Harvard Bioscience Inc. (NASDAQ:HBIO) was down 1.5% during trading on Monday . The stock traded as low as $2.60 and last traded at $2.61, with a volume of 62,285 shares trading hands. The stock had previously closed at $2.65.

Separately, Zacks Investment Research upgraded Harvard Bioscience from a “sell” rating to a “hold” rating in a research note on Tuesday, July 12th.

The stock’s market cap is $89.56 million. The company’s 50 day moving average is $2.88 and its 200-day moving average is $3.00.

Harvard Bioscience (NASDAQ:HBIO) last issued its quarterly earnings results on Thursday, July 28th. The company reported $0.03 earnings per share for the quarter, meeting the consensus estimate of $0.03. The company earned $26.10 million during the quarter, compared to analyst estimates of $26.60 million. On average, equities analysts expect that Harvard Bioscience Inc. will post $0.16 earnings per share for the current fiscal year.

Harvard Bioscience, Inc is a developer, manufacturer and marketer of a range of specialized products, apparatus and scientific instruments. The Company’s products are used to advance life science research at pharmaceutical and biotechnology companies, universities and government laboratories across the world.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.